# Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

> **NCT02788188** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 38 (actual)

## Conditions studied

- Middle East Respiratory Syndrome Coronavirus

## Interventions

- **BIOLOGICAL:** SAB-301
- **OTHER:** Normal (9%) Saline

## Key facts

- **NCT ID:** NCT02788188
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-28
- **Primary completion:** 2018-04-10
- **Final completion:** 2018-04-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788188, "Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02788188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*